Oncology readers curious about cell‑therapy progress will open this news piece on a biotech's clinical advancement in advanced liver cancer and implications.
Key Takeaways
- NMPA cleared an autologous GPC3 CAR-T to start a randomized confirmatory trial
- Phase I BEACON data showed manageable CRS and no ICANS or off-target toxicity
- GPC3 is overexpressed in over 70% of hepatocellular carcinomas, supporting target rationale